COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
16 hedge funds and large institutions have $555K invested in COSCIENS Biopharma Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.03% less ownership
Funds ownership: 0.05% → 0.03% (-0.03%)
6% less funds holding
Funds holding: 17 → 16 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
44% less capital invested
Capital invested by funds: $998K → $555K (-$443K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$127K |
| 2 |
Two Sigma Advisers
New York
|
+$69.4K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$26.3K |
| 4 |
DWM
Dorchester Wealth Management
Montreal,
Quebec, Canada
|
+$4.43K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$3.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$94K |
| 2 |
VF
Virtu Financial
New York
|
-$39K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$19K |
| 4 |
Renaissance Technologies
New York
|
-$14K |
| 5 |
Jane Street
New York
|
-$222 |
CSCI Hedge Fund Activity: Q3 2020 in Review
16 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2020, worth a combined $555K — down 44% from $998K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CSCI and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was Morgan Stanley, adding an estimated $127K. The largest seller was Ikarian Capital, exiting entirely with an estimated $94K sold.
- 16 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2020, down from 17 in Q2 2020.
- Funds reported $555K of COSCIENS Biopharma Inc. Common Stock stock for Q3 2020, down 44% quarter-over-quarter.
- 4 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2020 and 5 closed out, a net change of -1 holder.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2020 was Morgan Stanley, an estimated $127K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2020 was Ikarian Capital, an estimated $94K sold.
Based on aggregated 13F filings for Q3 2020.